Filing Flows

Filing Flows › Cardiff Oncology (CRDF) › Next earnings date

Cardiff Oncology (CRDF) earnings on Nov 12, 2026: what to expect

Cardiff Oncology (CRDF) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.13 (−$0.14 to −$0.12, 4 estimates) on revenue of $86K, against −$0.17 and $120K a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.

Report dateNov 12, 2026 (estimated)
Days to go4
EPS estimate−$0.13
Revenue estimate$86K
Beat rate75%

What to watch

Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:

Cardiff Oncology: revenue lines, growth year over year, Q2 2026Cardiff Oncology: revenue lines, growth year over year, Q2 2026Revenue-14%

Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.17 on revenue of $76K, against the analysts' −$0.13.

The last report

Cardiff Oncology reported revenue of $104K for the second quarter 2026 (-14% Y/Y), net loss $9.2M. How it makes money → · Every quarter →

Cardiff Oncology: EPS against the estimate, last 4 reportsCardiff Oncology: EPS against the estimate, last 4 reportsEstimateReported−$0.21−$0.17Nov 25−$0.20−$0.11Feb 26−$0.12−$0.18May 26−$0.16−$0.14Aug 26
Latest (Aug 26): Estimate −$0.16, Reported −$0.14.

Cardiff Oncology's latest quarter

Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.

Questions

When does CRDF report earnings?

Cardiff Oncology is expected to report on Nov 12, 2026 (estimated).

What are analysts expecting from Cardiff Oncology?

EPS of −$0.13 and revenue of $86K for the quarter.

Does Cardiff Oncology usually beat earnings?

It beat the consensus EPS estimate in 75% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.